Solid Biosciences
Advancing gene therapy candidates for Duchenne and other rare neuromuscular and cardiac diseases.
$9.77
After-hours close−0.01 (−0.10%)
At close$9.78(−3.46%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 116.61%Insiders 0.96%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 98.45M · Float 78.20M · 79.4% free float
Institutions13F, as of Jun 30, 2026
162 holders · 114.80M shares · 43 new positions · 101 increased · 37 reduced · 28 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 12.04M | 12.23% | +2.70M | Aug 14, 2026 |
| Perceptive Advisors LLC | 11.91M | 12.09% | 0 | Aug 14, 2026 |
| Bain Capital Life Sciences Investors, LLC | 9.81M | 9.96% | 0 | Aug 14, 2026 |
| Siren, L.L.C. | 7.69M | 7.81% | 0 | Aug 13, 2026 |
| BlackRock, Inc. | 6.93M | 7.04% | +1.98M | Aug 7, 2026 |
| FMR LLC | 6.88M | 6.98% | +3.27M | Aug 13, 2026 |
| Armistice Capital, LLC | 4.28M | 4.35% | +1.08M | Aug 14, 2026 |
| State Street Corp | 4.18M | 4.24% | +3.05M | Aug 7, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| RA Capital Management, L.P.incl. RA Capital Healthcare Fund, L.P., Peter Kolchinsky +1 more | 11.90% | 12.04M | 13D | Jun 24, 2026 ↗ |
| Perceptive Advisors LLCincl. Joseph Edelman, Perceptive Life Sciences Master Fund, Ltd. +1 more | 11.20% | 12.05M | 13D | Aug 14, 2026 ↗ |
| BCLS II Investco, LPincl. BCIP Life Sciences Associates, LP, BCLS II Equity Opportunities, LP +3 more | 8.80% | 8.60M | 13D | Mar 10, 2026 ↗ |
| Invus Public Equities, L.P. | 8.70% | 8.70M | 13G | May 5, 2026 ↗ |
| Commodore Capital LP | 7.60% | 5.83M | 13G | Feb 25, 2025 ↗ |
| Vestal Point Capital, LP | 7.50% | 5.82M | 13G | Feb 17, 2026 ↗ |
| Ryan Wilderincl. Vestal Point Capital, LP | 7.30% | 2.80M | 13G | Nov 14, 2024 ↗ |
| BlackRock, Inc. | 6.50% | 6.42M | 13G | Jul 30, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 10 percent owner | 11.90M | 12.09% | Jun 24, 2026 |
| Alexander Cumbo | director, officer: President and CEO | 235.4K | 0.24% | Feb 18, 2026 |
| Ian F. Smith | director | 138.1K | 0.14% | Jul 7, 2026 |
| Ilan Ganot | director | 126.8K | 0.13% | Feb 18, 2026 |
| David T. Howton | officer: Chief Operating Officer | 105.1K | 0.11% | Feb 18, 2026 |
| Kevin Tan | officer: CFO & Treasurer | 99.4K | 0.10% | Feb 18, 2026 |
| Gabriel Brooks | officer: Chief Medical Officer | 89.5K | 0.09% | Feb 18, 2026 |
| Jessie Hanrahan | officer: Chief Regulatory Officer | 74.3K | 0.08% | Feb 18, 2026 |
| Paul Herzich | officer: Chief Technology Officer | 72.6K | 0.07% | Feb 18, 2026 |
| Clare Kahn | director | 3.0K | 0.00% | Mar 13, 2025 |
7 ten-percent owners hold 22.01M shares by Form 4 — the 13D/G table above shows those stakes, the figure above counts officers and directors only · 15 people have not refiled in the last 18 months (17.72M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Feb 18, 2026 | Kevin Tanofficer: CFO & Treasurer | Sale | 5,404 | $5.82 | 99,422 |
| Feb 18, 2026 | Gabriel Brooksofficer: Chief Medical Officer | Sale | 0 | 89,466 | |
| Feb 18, 2026 | David T. Howtonofficer: Chief Operating Officer | Sale | 7,469 | $5.82 | 105,077 |
| Feb 18, 2026 | Paul Herzichofficer: Chief Technology Officer | Sale | 3,616 | $5.82 | 72,638 |
| Feb 18, 2026 | Ilan Ganotdirector | Sale | 2,658 | $5.82 | 27,474 |
| Feb 18, 2026 | Jessie Hanrahanofficer: Chief Regulatory Officer | Sale | 4,134 | $5.82 | 74,318 |
| Feb 18, 2026 | Alexander Cumbodirector, officer: President and CEO | Sale | 16,644 | $5.82 | 235,405 |
| Feb 4, 2026 | Paul Herzichofficer: Chief Technology Officer | Sale | 10,905 | $6.44 | 69,067 |
| Feb 4, 2026 | Jessie Hanrahanofficer: Chief Regulatory Officer | Sale | 12,348 | $6.44 | 70,327 |
| Feb 4, 2026 | Gabriel Brooksofficer: Chief Medical Officer | Sale | 12,616 | $6.44 | 84,092 |
CongressHouse and Senate disclosures
Not reported.